Ionis Pharmaceuticals has achieved a groundbreaking milestone with the FDA approval of Dawnzera, the first RNA-targeted prophylactic for hereditary angioedema (HAE). This innovative drug, previously known as donidalorsen, represents Ionis’ second wholly owned asset and is set to revolutionize the treatment landscape for patients with HAE. Dawnzera offers a superior profile compared to existing prophylactic options, boasting less frequent dosing and the convenience of at-home auto-injector administration.
Dawnzera’s approval is based on compelling data from the OASIS-HAE study, published in the New England Journal of Medicine, demonstrating its effectiveness in significantly reducing the monthly HAE attack rate by 81% compared to a placebo. Moreover, the therapy exhibited a remarkable 90% decrease in moderate-to-severe HAE attacks over 24 weeks, translating to a substantial enhancement in patients’ quality of life. Notably, patients who transitioned to Dawnzera from other prophylactics reported a seamless experience without an increase in attack frequency.
The Phase III OASISplus open-label extension study further reinforced Dawnzera’s efficacy, revealing a remarkable 94% reduction in the total mean attack rate from baseline after one year of treatment. Patient feedback has been overwhelmingly positive, with 84% expressing a preference for Dawnzera over their prior prophylactic regimen. Administered subcutaneously every four weeks, Dawnzera leverages a conjugated antisense oligonucleotide to target prekallikrein mRNA, ultimately reducing levels of the PKK protein responsible for triggering HAE symptoms.
Dawnzera’s approval heralds a new era in rare disease treatment, aligning with recent groundbreaking approvals in the field. Notable milestones include Jazz Pharmaceuticals’ Modeyso for the treatment of diffuse midline glioma, Insmed’s Brinsupri for non-cystic fibrosis bronchiectasis, and Precigen’s Papzimeos for recurrent respiratory papillomatosis. Ionis’ success with Dawnzera underscores its commitment to advancing therapeutic options for patients with rare diseases, setting a high bar for innovation and patient care in the biopharmaceutical industry.
Key Takeaways:
– Dawnzera, Ionis Pharmaceuticals’ RNA-targeted prophylactic, has received FDA approval for the prevention of hereditary angioedema attacks.
– The therapy offers superior benefits over existing options, with reduced dosing frequency and at-home administration for enhanced patient convenience.
– Clinical data from the OASIS-HAE study demonstrate Dawnzera’s efficacy in significantly lowering HAE attack rates and improving patients’ quality of life.
– Dawnzera’s approval reflects a trend of groundbreaking advancements in rare disease therapeutics, highlighting the industry’s commitment to innovation and patient-centered care.
Tags: immunotherapy
Read more on biospace.com